Geron Stock Price, News & Analysis (NASDAQ:GERN)

$1.91 -0.08 (-4.02 %)
(As of 01/19/2018 04:18 AM ET)
Previous Close$1.99
Today's Range$1.89 - $2.00
52-Week Range$1.74 - $3.15
Volume1.61 million shs
Average Volume1.66 million shs
Market Capitalization$304.13 million
P/E Ratio-10.61
Dividend YieldN/A
Beta2.59

About Geron (NASDAQ:GERN)

Geron logoGeron Corporation (Geron) is a biopharmaceutical company, which supports the clinical stage development of a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies by Janssen Biotech, Inc. (Janssen). The Company is engaged in the development of therapeutic products for oncology. Using its nucleic acid chemistry, Geron designed Imetelstat to be an oligonucleotide that binds with high affinity to the ribonucleic acid (RNA) template of telomerase, thereby directly inhibiting telomerase activity. Janssen is engaged in the development of Imetelstat with two clinical trials, such as a Phase II trial in myelofibrosis (MF), referred to as IMbark, and a Phase II/III trial in myelodysplastic syndromes (MDS) referred to as IMerge. Imetelstat is a lipid conjugated 13-mer oligonucleotide that is designed to be complementary to and bind with high affinity to the RNA template of telomerase, thereby directly inhibiting telomerase activity.

Receive GERN News and Ratings via Email

Sign-up to receive the latest news and ratings for GERN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryBiotechnology
SectorHealthcare
SymbolNASDAQ:GERN
CUSIP37416310
Phone+1-650-4737700

Debt

Debt-to-Equity RatioN/A
Current Ratio16.51%
Quick Ratio16.51%

Price-To-Earnings

Trailing P/E Ratio-10.6111111111111
Forward P/E Ratio-11.24
P/E GrowthN/A

Sales & Book Value

Annual Sales$6.16 million
Price / Sales49.37
Cash FlowN/A
Price / CashN/A
Book Value$0.77 per share
Price / Book2.48

Profitability

Trailing EPS($0.18)
Net Income$-29,530,000.00
Net Margins-2,992.67%
Return on Equity-25.14%
Return on Assets-23.29%

Miscellaneous

Employees18
Outstanding Shares159,230,000

Geron (NASDAQ:GERN) Frequently Asked Questions

What is Geron's stock symbol?

Geron trades on the NASDAQ under the ticker symbol "GERN."

How were Geron's earnings last quarter?

Geron Co. (NASDAQ:GERN) released its quarterly earnings results on Wednesday, November, 1st. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.05) by $0.01. The biopharmaceutical company had revenue of $0.16 million for the quarter, compared to analysts' expectations of $0.40 million. Geron had a negative return on equity of 25.14% and a negative net margin of 2,992.67%. The business's revenue for the quarter was down 96.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.02) earnings per share. View Geron's Earnings History.

When will Geron make its next earnings announcement?

Geron is scheduled to release their next quarterly earnings announcement on Wednesday, March, 7th 2018. View Earnings Estimates for Geron.

Where is Geron's stock going? Where will Geron's stock price be in 2018?

4 brokerages have issued 1-year price objectives for Geron's shares. Their forecasts range from $2.50 to $5.00. On average, they expect Geron's share price to reach $4.17 in the next year. View Analyst Ratings for Geron.

Are investors shorting Geron?

Geron saw a increase in short interest in the month of December. As of December 29th, there was short interest totalling 30,650,443 shares, an increase of 0.0% from the December 15th total of 30,657,052 shares. Based on an average trading volume of 1,920,753 shares, the days-to-cover ratio is presently 16.0 days. Approximately 19.4% of the shares of the stock are short sold.

Who are some of Geron's key competitors?

Who are Geron's key executives?

Geron's management team includes the folowing people:

  • Hoyoung Huh Ph.D., Independent Chairman of the Board (Age 48)
  • John A. Scarlett M.D., President, Chief Executive Officer, Director (Age 66)
  • Olivia K. Bloom, Chief Financial Officer, Executive Vice President - Finance, Treasurer (Age 46)
  • Stephen N. Rosenfield J.D., Executive Vice President, General Counsel and Corporate Secretary (Age 62)
  • Andrew J. Grethlein Ph.D., Executive Vice President - Development and Technical Operations (Age 50)
  • Melissa A. Kelly Behrs, Executive Vice President - Business Development and Portfolio and Alliance Management (Age 51)
  • Susan M. Molineaux Ph.D., Director (Age 63)
  • Daniel M. Bradbury, Independent Director (Age 56)
  • Karin Eastham CPA, Independent Director (Age 67)
  • V. Bryan Lawlis Jr. Ph.D., Independent Director (Age 65)

Who owns Geron stock?

Geron's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Creative Planning (0.19%). View Institutional Ownership Trends for Geron.

Who bought Geron stock? Who is buying Geron stock?

Geron's stock was bought by a variety of institutional investors in the last quarter, including Creative Planning. View Insider Buying and Selling for Geron.

How do I buy Geron stock?

Shares of Geron can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Geron's stock price today?

One share of Geron stock can currently be purchased for approximately $1.91.

How big of a company is Geron?

Geron has a market capitalization of $304.13 million and generates $6.16 million in revenue each year. The biopharmaceutical company earns $-29,530,000.00 in net income (profit) each year or ($0.18) on an earnings per share basis. Geron employs 18 workers across the globe.

How can I contact Geron?

Geron's mailing address is 149 Commonwealth Dr Ste 2070, MENLO PARK, CA 94025-1133, United States. The biopharmaceutical company can be reached via phone at +1-650-4737700 or via email at [email protected]


MarketBeat Community Rating for Geron (GERN)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  191 (Vote Outperform)
Underperform Votes:  147 (Vote Underperform)
Total Votes:  338
MarketBeat's community ratings are surveys of what our community members think about Geron and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Geron (NASDAQ:GERN) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyHold
Consensus Rating Score: 2.502.502.502.40
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $4.17$4.17$4.17$4.17
Price Target Upside: 96.54% upside96.54% upside45.18% upside45.18% upside

Geron (NASDAQ:GERN) Consensus Price Target History

Price Target History for Geron (NASDAQ:GERN)

Geron (NASDAQ:GERN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/3/2017Needham & Company LLCReiterated RatingHoldN/AView Rating Details
11/3/2017Stifel NicolausReiterated RatingHold$2.50N/AView Rating Details
7/4/2017FBR & CoReiterated RatingBuyMediumView Rating Details
4/12/2017Piper Jaffray CompaniesReiterated RatingOverweight$5.00LowView Rating Details
9/20/2016BTIG ResearchReiterated RatingNeutralN/AView Rating Details
(Data available from 1/19/2016 forward)

Earnings

Geron (NASDAQ:GERN) Earnings History and Estimates Chart

Earnings by Quarter for Geron (NASDAQ:GERN)

Geron (NASDAQ GERN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/7/2018        
11/1/2017Q3 2017($0.05)($0.04)$0.40 million$0.16 millionViewN/AView Earnings Details
8/9/2017Q2 2017($0.05)($0.04)$0.38 million$0.17 millionViewN/AView Earnings Details
5/9/2017Q1 2017($0.05)($0.05)$0.27 million$0.54 millionViewN/AView Earnings Details
3/1/2017Q416($0.06)($0.05)$0.18 million$0.09 millionViewListenView Earnings Details
11/3/2016Q316($0.06)($0.02)$0.22 million$5.10 millionViewListenView Earnings Details
8/3/2016Q216($0.07)($0.05)$0.38 million$0.21 millionViewListenView Earnings Details
5/5/2016Q116($0.06)($0.06)$0.26 million$0.74 millionViewListenView Earnings Details
2/25/2016Q415($0.05)($0.05)$0.32 million$0.22 millionViewListenView Earnings Details
11/5/2015Q315$0.11$0.17$17.87 million$35.40 millionViewListenView Earnings Details
8/5/2015Q2 15($0.06)($0.05)$0.40 million$0.25 millionViewN/AView Earnings Details
4/30/2015Q1($0.06)($0.06)$0.32 million$0.54 millionViewN/AView Earnings Details
3/3/2015Q4$0.17($0.06)$35.35 million$0.18 millionViewListenView Earnings Details
11/5/2014Q314($0.06)($0.06)$0.28 million$0.16 millionViewN/AView Earnings Details
8/11/2014Q214($0.06)($0.06)$0.22 million$0.34 millionViewListenView Earnings Details
5/1/2014Q114($0.06)($0.06)$0.35 million$0.47 millionViewListenView Earnings Details
3/27/2014($0.06)($0.07)ViewN/AView Earnings Details
3/17/2014Q413($0.07)($0.07)$0.35 millionViewListenView Earnings Details
11/7/2013Q313($0.06)($0.06)$0.49 million$0.18 millionViewListenView Earnings Details
8/8/2013Q2 2013($0.07)($0.07)$0.50 million$0.11 millionViewListenView Earnings Details
4/25/2013Q1 2013($0.08)($0.09)$0.71 million$0.77 millionViewListenView Earnings Details
3/12/2013Q4 2012($0.14)($0.12)$0.50 million$0.69 millionViewListenView Earnings Details
10/30/2012Q312($0.14)($0.13)$0.38 million$0.64 millionViewN/AView Earnings Details
7/31/2012($0.15)($0.14)ViewN/AView Earnings Details
5/2/2012($0.18)($0.15)ViewN/AView Earnings Details
3/7/2012Q4 2011($0.20)($0.22)ViewN/AView Earnings Details
11/3/2011($0.18)($0.16)ViewN/AView Earnings Details
7/28/2011($0.18)($0.17)ViewN/AView Earnings Details
4/27/2011($0.19)($0.20)ViewN/AView Earnings Details
2/24/2011($0.19)($0.39)ViewN/AView Earnings Details
10/28/2010Q3 2010($0.20)($0.19)ViewN/AView Earnings Details
7/29/2010Q2 2010($0.19)($0.18)ViewN/AView Earnings Details
4/28/2010Q1 2010($0.20)($0.18)ViewN/AView Earnings Details
2/25/2010Q4 2009($0.17)($0.20)ViewN/AView Earnings Details
10/29/2009Q3 2009($0.21)($0.17)ViewN/AView Earnings Details
7/30/2009Q2 2009($0.19)($0.23)ViewN/AView Earnings Details
4/29/2009Q1 2009($0.20)($0.20)ViewN/AView Earnings Details
2/26/2009Q4 2008($0.21)($0.22)ViewN/AView Earnings Details
10/30/2008Q3 2008($0.20)($0.22)ViewN/AView Earnings Details
7/30/2008Q2 2008($0.20)($0.17)ViewN/AView Earnings Details
4/29/2008Q1 2008($0.18)($0.18)ViewN/AView Earnings Details
2/27/2008Q4 2007($0.12)($0.22)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Geron (NASDAQ:GERN) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.17 EPS
Next Year EPS Consensus Estimate: $-0.02 EPS

Dividends

Dividend History for Geron (NASDAQ:GERN)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Geron (NASDAQ GERN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 7.10%
Institutional Ownership Percentage: 39.21%
Insider Trades by Quarter for Geron (NASDAQ:GERN)
Institutional Ownership by Quarter for Geron (NASDAQ:GERN)

Geron (NASDAQ GERN) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/29/2015Olivia Kyusuk BloomCFOSell2,380$3.84$9,139.20View SEC Filing  
3/18/2015Thomas HofstaetterDirectorSell70,000$4.10$287,000.00View SEC Filing  
5/29/2014Melissa Kelly BehrsEVPSell4,826$2.10$10,134.60View SEC Filing  
5/29/2014Olivia Kyusuk BloomCFOSell3,379$2.10$7,095.90View SEC Filing  
5/9/2014Daniel BradburyDirectorBuy142,776$1.75$249,858.00142,776View SEC Filing  
4/1/2014Melissa Kelly BehrsEVPSell12,310$2.13$26,220.30147,841View SEC Filing  
4/1/2014Olivia Kyusuk BloomCFOSell7,435$2.13$15,836.5585,347View SEC Filing  
4/1/2013John A ScarlettCEOBuy50,000$1.03$51,500.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Geron (NASDAQ GERN) News Headlines

Source:
DateHeadline
Geron Co. (GERN) Given Consensus Rating of "Hold" by AnalystsGeron Co. (GERN) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - January 16 at 1:38 AM
Geron (GERN) Rating Increased to Sell at BidaskClubGeron (GERN) Rating Increased to Sell at BidaskClub
www.americanbankingnews.com - January 14 at 11:50 PM
San Leon Energy Discussions with Potential Offerors CGUP, Geron TerminatedSan Leon Energy Discussions with Potential Offerors CGUP, Geron Terminated
finance.yahoo.com - January 5 at 9:39 AM
Geron (GERN) Downgraded by Zacks Investment ResearchGeron (GERN) Downgraded by Zacks Investment Research
www.americanbankingnews.com - January 2 at 12:44 PM
Contrasting G1 Therapeutics (GTHX) and Geron (GERN)Contrasting G1 Therapeutics (GTHX) and Geron (GERN)
www.americanbankingnews.com - December 28 at 1:10 AM
Geron Co. (GERN) Receives Consensus Rating of "Hold" from AnalystsGeron Co. (GERN) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - December 22 at 1:34 AM
ETFs with exposure to Geron Corp. : December 18, 2017ETFs with exposure to Geron Corp. : December 18, 2017
finance.yahoo.com - December 18 at 5:16 PM
BRIEF-Geron Co Appoints General ManagerBRIEF-Geron Co Appoints General Manager
finance.yahoo.com - December 15 at 9:57 AM
Short Interest in Geron Co. (GERN) Expands By 5.8%Short Interest in Geron Co. (GERN) Expands By 5.8%
www.americanbankingnews.com - December 13 at 1:10 AM
Geron Reports Imetelstat Presentations at American Society of Hematology Annual MeetingGeron Reports Imetelstat Presentations at American Society of Hematology Annual Meeting
finance.yahoo.com - December 12 at 9:58 AM
Geron: Its Breakout Time - Seeking AlphaGeron: It's Breakout Time - Seeking Alpha
seekingalpha.com - December 7 at 5:44 PM
ETFs with exposure to Geron Corp. : December 7, 2017ETFs with exposure to Geron Corp. : December 7, 2017
finance.yahoo.com - December 7 at 5:44 PM
2 Reasons Geron Corporation Took a Pounding in November2 Reasons Geron Corporation Took a Pounding in November
www.fool.com - December 6 at 10:58 AM
1 High-Risk Penny Stock That May Be Worth Buying1 High-Risk Penny Stock That May Be Worth Buying
www.fool.com - December 4 at 4:27 PM
ETFs with exposure to Geron Corp. : November 27, 2017ETFs with exposure to Geron Corp. : November 27, 2017
finance.yahoo.com - November 27 at 5:42 PM
Geron Corporation (GERN) Given Average Rating of "Hold" by BrokeragesGeron Corporation (GERN) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - November 27 at 2:06 AM
Biotech Stock Performance Review -- BioCryst Pharma, Celgene, Exelixis, and GeronBiotech Stock Performance Review -- BioCryst Pharma, Celgene, Exelixis, and Geron
www.prnewswire.com - November 21 at 6:40 AM
Geron Corp (GERN) Reported First Patient Dosed in Expanded Part 1 of IMerge Clinical Trial in Myelodysplastic ... - StreetInsider.comGeron Corp (GERN) Reported First Patient Dosed in Expanded Part 1 of IMerge Clinical Trial in Myelodysplastic ... - StreetInsider.com
www.streetinsider.com - November 21 at 12:37 AM
Geron Corp (GERN) Reported First Patient Dosed in Expanded Part 1 of IMerge Clinical Trial in Myelodysplastic SyndromesGeron Corp (GERN) Reported First Patient Dosed in Expanded Part 1 of IMerge Clinical Trial in Myelodysplastic Syndromes
www.streetinsider.com - November 20 at 7:36 PM
Geron Announces First Patient Dosed in Expanded Part 1 of IMerge Clinical Trial in Myelodysplastic SyndromesGeron Announces First Patient Dosed in Expanded Part 1 of IMerge Clinical Trial in Myelodysplastic Syndromes
finance.yahoo.com - November 20 at 7:36 PM
Geron Short Interest Is Dropping Steadily - Seeking AlphaGeron Short Interest Is Dropping Steadily - Seeking Alpha
seekingalpha.com - November 18 at 6:15 PM
ETFs with exposure to Geron Corp. : November 17, 2017ETFs with exposure to Geron Corp. : November 17, 2017
finance.yahoo.com - November 17 at 5:36 PM
Today’s Research Reports on Trending Tickers: Gilead Sciences and Geron CorporationToday’s Research Reports on Trending Tickers: Gilead Sciences and Geron Corporation
finance.yahoo.com - November 16 at 2:41 PM
Geron Announces November Investor Conference Presentation WebcastsGeron Announces November Investor Conference Presentation Webcasts
finance.yahoo.com - November 8 at 7:54 AM
ETFs with exposure to Geron Corp. : November 6, 2017ETFs with exposure to Geron Corp. : November 6, 2017
finance.yahoo.com - November 7 at 12:52 AM
Stifel Nicolaus Reiterates Hold Rating for Geron Corporation (GERN)Stifel Nicolaus Reiterates Hold Rating for Geron Corporation (GERN)
www.americanbankingnews.com - November 4 at 6:42 PM
Needham & Company LLC Reaffirms Hold Rating for Geron Corporation (GERN)Needham & Company LLC Reaffirms Hold Rating for Geron Corporation (GERN)
www.americanbankingnews.com - November 3 at 11:58 PM
Geron Corp. :GERN-US: Earnings Analysis: Q3, 2017 By the Numbers : November 3, 2017Geron Corp. :GERN-US: Earnings Analysis: Q3, 2017 By the Numbers : November 3, 2017
finance.yahoo.com - November 3 at 10:23 AM
Geron (GERN) Q3 Loss Narrower Than Expected, Sales Miss - NasdaqGeron (GERN) Q3 Loss Narrower Than Expected, Sales Miss - Nasdaq
www.nasdaq.com - November 2 at 8:27 PM
Edited Transcript of GERN earnings conference call or presentation 1-Nov-17 8:30pm GMTEdited Transcript of GERN earnings conference call or presentation 1-Nov-17 8:30pm GMT
finance.yahoo.com - November 2 at 8:27 PM
Geron (GERN) Q3 Loss Narrower Than Expected, Sales MissGeron (GERN) Q3 Loss Narrower Than Expected, Sales Miss
finance.yahoo.com - November 2 at 8:27 PM
Geron Corp. – Value Analysis (NASDAQ:GERN) : November 2, 2017Geron Corp. – Value Analysis (NASDAQ:GERN) : November 2, 2017
finance.yahoo.com - November 2 at 8:27 PM
Geron Corporation (GERN) Given Average Recommendation of "Hold" by BrokeragesGeron Corporation (GERN) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - November 2 at 5:30 AM
Geron Corp (GERN) Tops Q2 EPS by 1c - StreetInsider.com - StreetInsider.comGeron Corp (GERN) Tops Q2 EPS by 1c - StreetInsider.com - StreetInsider.com
www.streetinsider.com - November 2 at 1:18 AM
Geron Corporations (GERN) CEO Dr. John Scarlett on Q3 2017 Results - Earnings Call Transcript - Seeking AlphaGeron Corporation's (GERN) CEO Dr. John Scarlett on Q3 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - November 2 at 1:18 AM
EARNINGS SUMMARY: Details of Geron Corporation Q3 Earnings ReportEARNINGS SUMMARY: Details of Geron Corporation Q3 Earnings Report
www.rttnews.com - November 1 at 8:16 PM
Finally, Geron IMerges With Some Movement In MDSFinally, Geron IMerges With Some Movement In MDS
seekingalpha.com - November 1 at 8:16 PM
Geron Corp. breached its 50 day moving average in a Bullish Manner : GERN-US : November 1, 2017Geron Corp. breached its 50 day moving average in a Bullish Manner : GERN-US : November 1, 2017
finance.yahoo.com - November 1 at 8:15 PM
Geron (GERN) in Focus: Stock Moves 9.2% HigherGeron (GERN) in Focus: Stock Moves 9.2% Higher
finance.yahoo.com - November 1 at 8:15 PM
Geron Announces Presentations at American Society of Hematology Annual MeetingGeron Announces Presentations at American Society of Hematology Annual Meeting
finance.yahoo.com - November 1 at 8:15 PM
Geron Corporation to Host Earnings CallGeron Corporation to Host Earnings Call
finance.yahoo.com - November 1 at 8:15 PM
Geron Corporation Reports Third Quarter 2017 Financial ResultsGeron Corporation Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 1 at 8:15 PM
Geron reports 3Q lossGeron reports 3Q loss
finance.yahoo.com - November 1 at 8:15 PM
Geron Corporation (GERN) Issues  Earnings Results, Beats Estimates By $0.01 EPSGeron Corporation (GERN) Issues Earnings Results, Beats Estimates By $0.01 EPS
www.americanbankingnews.com - November 1 at 5:28 PM
Geron Corp (GERN) Announces FDA Fast Track Designation Granted to Imetelstat for Lower Risk Myelodysplastic ... - StreetInsider.comGeron Corp (GERN) Announces FDA Fast Track Designation Granted to Imetelstat for Lower Risk Myelodysplastic ... - StreetInsider.com
www.streetinsider.com - November 1 at 1:13 AM
Geron Corp (GERN) Announces FDA Fast Track Designation Granted to Imetelstat for Lower Risk Myelodysplastic SyndromesGeron Corp (GERN) Announces FDA Fast Track Designation Granted to Imetelstat for Lower Risk Myelodysplastic Syndromes
www.streetinsider.com - October 31 at 8:11 PM
Geron Announces Fast Track Designation Granted to Imetelstat for Lower Risk Myelodysplastic SyndromesGeron Announces Fast Track Designation Granted to Imetelstat for Lower Risk Myelodysplastic Syndromes
finance.yahoo.com - October 31 at 8:11 PM
Why Geron Corporation Stock Is Jumping TodayWhy Geron Corporation Stock Is Jumping Today
www.fool.com - October 31 at 1:35 PM
Whats in the Cards for Geron (GERN) this Earnings Season?What's in the Cards for Geron (GERN) this Earnings Season?
finance.yahoo.com - October 28 at 4:27 AM
What's in the Cards for Geron (GERN) this Earnings Season?What's in the Cards for Geron (GERN) this Earnings Season?
finance.yahoo.com - October 28 at 4:27 AM

SEC Filings

Geron (NASDAQ:GERN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Geron (NASDAQ:GERN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Geron (NASDAQ GERN) Stock Chart for Friday, January, 19, 2018

Loading chart…

This page was last updated on 1/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.